KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Merck (MRK) Debt Ratio (2009 - 2026)

Merck (MRK) reported Debt Ratio of 0.38 for Q1 2026, up 26.11% year-over-year from 0.3 in Q1 2025, and up 5.88% on a QoQ basis from 0.36 in Q4 2025.

Merck (MRK) has 18 years of Debt Ratio data on file, last reported at 0.38 in Q1 2026.

  • Quarterly Debt Ratio rose 26.11% year-over-year to 0.38 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.38 (up 26.11% YoY) and the FY2025 annual result came in at 0.36, up 13.76% from the prior year.
  • Debt Ratio climbed to 0.38 in Q1 2026 per MRK's latest filing, from 0.36 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.38 in Q1 2026 and bottomed at 0.28 in Q4 2022.
  • The 5-year median for Debt Ratio is 0.32 (2025), against an average of 0.32.
  • The widest annual swing landed in 2022, when Debt Ratio declined 13.36%; it then advanced 26.11% in 2026.
  • Tracing MRK's Debt Ratio over 5 years: stood at 0.28 in 2022, then rose by 16.88% to 0.33 in 2023, then retreated by 3.56% to 0.32 in 2024, then climbed by 13.76% to 0.36 in 2025, then advanced by 5.88% to 0.38 in 2026.
  • Per Business Quant, the three latest MRK Debt Ratio figures stand at 0.38 (Q1 2026), 0.36 (Q4 2025), and 0.32 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.37
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 0.27
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 0.47
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.38
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.62
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.39
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 0.31
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.51
10 Gsk 88.34 Bn 83.66 Bn - 0.29

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.38
Dec 31, 2025 0.36
Sep 30, 2025 0.32
Jun 30, 2025 0.30
Mar 31, 2025 0.30
Dec 31, 2024 0.32
Sep 30, 2024 0.32
Jun 30, 2024 0.34
Mar 31, 2024 0.32
Dec 31, 2023 0.33
Sep 30, 2023 0.33
Jun 30, 2023 0.35
Mar 31, 2023 0.29
Dec 31, 2022 0.28
Sep 30, 2022 0.28
Jun 30, 2022 0.30
Mar 31, 2022 0.30
Dec 31, 2021 0.31
Sep 30, 2021 0.28
Jun 30, 2021 0.29
Mar 31, 2021 0.34
Dec 31, 2020 0.35
Sep 30, 2020 0.32
Jun 30, 2020 0.34
Mar 31, 2020 0.33
Dec 31, 2019 0.31
Sep 30, 2019 0.31
Jun 30, 2019 0.32
Mar 31, 2019 0.31
Dec 31, 2018 0.30
Sep 30, 2018 0.28
Jun 30, 2018 0.27
Mar 31, 2018 0.27
Dec 31, 2017 0.28
Sep 30, 2017 0.29
Jun 30, 2017 0.27
Mar 31, 2017 0.29
Dec 31, 2016 0.26
Sep 30, 2016 0.26
Jun 30, 2016 0.25
Mar 31, 2016 0.26
Dec 31, 2015 0.26
Sep 30, 2015 0.26
Jun 30, 2015 0.26
Mar 31, 2015 0.28
Dec 31, 2014 0.22
Sep 30, 2014 0.27
Jun 30, 2014 0.24
Mar 31, 2014 0.26
Dec 31, 2013 0.24
Sep 30, 2013 0.25
Jun 30, 2013 0.26
Dec 31, 2012 0.19
Jun 30, 2012 0.18
Mar 31, 2012 0.17
Dec 31, 2011 0.17
Sep 30, 2011 0.17
Jun 30, 2011 0.17
Mar 31, 2011 0.17
Dec 31, 2010 0.17
Sep 30, 2010 0.17
Jun 30, 2010 0.17
Mar 31, 2010 0.17
Dec 31, 2009 0.16
Sep 30, 2009 0.27
Jun 30, 2009 0.28